A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Sadeleştirilmiş öğe sayfası
dc.contributor.authorAbali, Huseyin
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOnal, Cem
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorArtac, Mehmet
dc.contributor.authorCamci, Celaletdin
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorBudakoglu, Burcin
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorGoktas, Burce
dc.contributor.authorOzdener, Fatih
dc.contributor.authorBaygul, Arzu
dc.date.accessioned2025-10-16T15:25:54Z
dc.date.issued2018
dc.description.abstractGastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA, JAN 18-20, 2018
dc.identifier.doi10.1200/JCO.2018.36.4\_suppl.26
dc.identifier.otherWOS:000436174100026
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8317
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleA study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS